Tenofovir Bis(Isopropyloxycarbonyloxymethyl) Ester
B-Cell Non-Hodgkin Lymphoma
University Health Network, TorontoSmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
306 Active assets in the B-Cell Non-Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vindesine Children's Cancer Group, China | Phase 4 | BBB |
Anti-Cd20/Cd3 Monoclonal Antibody Regn1979 University of Birmingham | Phase 3 | BBB |
Methotrexate Children's Cancer Group, China | Phase 4 | BBB |
Cytarabine Children's Cancer Group, China | Phase 4 | BBB |
Camustine Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Tenofovir Bis(Isopropyloxycarbonyloxymethyl) Ester is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →